Finance

AbbVie's ABBV-295 Shows 7.8%-9.8% Weight Loss in Phase 1

AbbVie’s ABBV-295 Phase 1 topline shows dose-dependent weight loss of about 7.75% to 9.79% at week 12, across 2 mg to 14 mg doses. The data point to potential for obesity management beyond Novo Nordisk, while remaining early and needing corroboration.

📅 March 09, 2026
⏱️ 2 min read
AbbVie's ABBV-295 Shows 7.8%-9.8% Weight Loss in Phase 1

Key Takeaways

  • ABBV-295 topline Phase 1 shows dose-dependent weight loss of roughly 7.75%–9.79% at Week 12.
  • Dose-ranging tested from 2 mg to 14 mg.
  • Generally well tolerated with mild gastrointestinal adverse events as most common.
  • AbbVie and Gubra A/S license for GUB014295 announced in March 2025.
  • Analysts’ view: average target around $241.24 with higher targets at RBC ($260), Barclays ($275), and Piper Sandler ($299).

People Involved

  • No specific individuals mentioned

Entities Involved

  • AbbVie Inc. (ABBV) Pharmaceutical company developing ABBV-295
  • Gubra A/S Biotech company licensed to develop GUB014295
  • Novo Nordisk Industry peer leading obesity therapies

MarketMoodz Analysis

The topline readout suggests AbbVie could extend its obesity earnings runway if ABBV-295 demonstrates sustained efficacy and safety in mid-stage trials, potentially enhancing pricing power with payers. The Gubra license adds optionality for speed-to-market or partnered development, increasing optionality around the obesity franchise.

Investors should view these Phase 1 signals in the context of a space led by Novo Nordisk, where early gains frequently hinge on safety profiles and real-world adherence. History shows several Phase 1 signals fade in later trials; a disciplined risk framework is essential.

Near-term catalysts include Phase 2 readouts, dose-ranging efficacy signals, and any safety flags, plus clarity on regulatory timelines and potential commercialization. Watch for payer negotiations, competitive dynamics, and how the data translate into margin- and revenue-impact for AbbVie.

Source: Original Article

Get AI-Powered Market Insights

Stay ahead of market-moving events with our real-time analysis and stock ratings.

Start Your Free Trial